Nuvation Bio Inc.(NUVB)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Nuvation Bio Inc. (NUVB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NUVB at 37.9/100 on a 32-signal composite quality model, placing it at rank #2,219 of 2,960 stocks — the bottom half of the AI-ranked universe. NUVB scores in the top quartile across institutional flow (99.7), revenue growth (99.3). Areas of concern include free cash flow (7.6) and profitability (8.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Nuvation Bio Inc. reports quarterly revenue of $31.7M, net income of $-62.8M. Top institutional holders of NUVB by reported 13-F value include FMR, BlackRock, Decheng Capital, based on the most recent SEC filings. NUVB trades on the NYSE exchange and files with the SEC under CIK 1811063. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvation Bio Inc. directly from SEC EDGAR.